Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market

Lupin Ltd has signed a non-exclusive patent licence agreement with Takeda Pharmaceutical to commercialise Vonoprazan tablets in India. The drug, approved for various gastrointestinal conditions, will be marketed as Lupivon in 10 mg and 20 mg strengths. This agreement aims to enhance Lupin's gastroenterology portfolio and address unmet patient needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mlbgFur
via IFTTT